Literature DB >> 3513880

Effect of vasoactive peptides on prostacyclin synthesis in man.

S E Barrow, C T Dollery, D J Heavey, N E Hickling, J M Ritter, J Vial.   

Abstract

Bradykinin, angiotensin II, arginine vasopressin (AVP) or des-amino-D-arginine vasopressin (DDAVP) were administered by intravenous infusion to 10 healthy men. The concentration of 6-oxo-prostaglandin F1 alpha (6-oxo-PGF1 alpha), the stable hydrolysis product of prostacyclin (PGI2), was measured in plasma using gas chromatography/negative ion chemical ionisation mass spectrometry. Dose-related increases in plasma concentrations of 6-oxo-PGF1 alpha occurred during administration of bradykinin (100-3200 ng kg-1 min-1). The concentrations of 6-oxo-PGF1 alpha rose from baseline values in the range less than 1.0-4.9 pg ml-1 to 24.9-47.6 pg ml-1 at maximum tolerated infusion rates. There were no changes in the concentrations of 6-oxo-PGF1 alpha during administration of angiotensin II, AVP or DDAVP at infusion rates which caused haemodynamic changes.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3513880      PMCID: PMC1916907          DOI: 10.1111/j.1476-5381.1986.tb10177.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  16 in total

1.  Bradykinin as a vasodilator in man.

Authors:  R H FOX; R GOLDSMITH; D J KIDD; G P LEWIS
Journal:  J Physiol       Date:  1961-08       Impact factor: 5.182

2.  Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls.

Authors:  S Moncada; J R Vane
Journal:  N Engl J Med       Date:  1979-05-17       Impact factor: 91.245

3.  Effect of bradykinin and thrombin on prostacyclin synthesis in endothelial cells from calf and pig aorta and human umbilical cord vein.

Authors:  S L Hong
Journal:  Thromb Res       Date:  1980-06-15       Impact factor: 3.944

4.  Plasma 6-keto-prostaglandin F1alpha: fact or fiction.

Authors:  M Greaves; F E Preston
Journal:  Thromb Res       Date:  1982-05-01       Impact factor: 3.944

5.  Release of prostacyclin in vivo and its role in man.

Authors:  J M Ritter; S E Barrow; I A Blair; C T Dollery
Journal:  Lancet       Date:  1983-02-12       Impact factor: 79.321

6.  Prostacyclin is not a circulating hormone in man.

Authors:  I A Blair; S E Barrow; K A Waddell; P J Lewis; C T Dollery
Journal:  Prostaglandins       Date:  1982-04

7.  DDAVP stimulates prostacyclin production.

Authors:  J J Belch; M Small; F McKenzie; P A Hill; G D Lowe; D E McIntyre; C D Forbes; C R Prentice
Journal:  Thromb Haemost       Date:  1982-04-30       Impact factor: 5.249

8.  Evidence for a direct stimulatory effect of prostacyclin on renin release in man.

Authors:  C Patrono; F Pugliese; G Ciabattoni; P Patrignani; A Maseri; S Chierchia; B A Peskar; G A Cinotti; B M Simonetti; A Pierucci
Journal:  J Clin Invest       Date:  1982-01       Impact factor: 14.808

9.  Estimated rate of prostacyclin secretion into the circulation of normal man.

Authors:  G A FitzGerald; A R Brash; P Falardeau; J A Oates
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

10.  Prostacyclin release and the modulation of some vasoactive hormones.

Authors:  K M Mullane; S Moncada
Journal:  Prostaglandins       Date:  1980-07
View more
  16 in total

1.  Angioedema due to ACE inhibitors: increased risk in patients of African origin.

Authors:  C R Gibbs; G Y Lip; D G Beevers
Journal:  Br J Clin Pharmacol       Date:  1999-12       Impact factor: 4.335

2.  Local inhibition of converting enzyme and vascular responses to angiotensin and bradykinin in the human forearm.

Authors:  N Benjamin; J R Cockcroft; J G Collier; C T Dollery; J M Ritter; D J Webb
Journal:  J Physiol       Date:  1989-05       Impact factor: 5.182

3.  Differential effect of aspirin on thromboxane and prostaglandin biosynthesis in man.

Authors:  J M Ritter; J R Cockcroft; H S Doktor; J Beacham; S E Barrow
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

Review 4.  ACE inhibitor-induced angioedema. Incidence, prevention and management.

Authors:  W Vleeming; J G van Amsterdam; B H Stricker; D J de Wildt
Journal:  Drug Saf       Date:  1998-03       Impact factor: 5.606

5.  Integrated pharmacokinetics and pharmacodynamics of epoprostenol in healthy subjects.

Authors:  Laurent B Nicolas; Andreas Krause; Marcelo M Gutierrez; Jasper Dingemanse
Journal:  Br J Clin Pharmacol       Date:  2012-12       Impact factor: 4.335

6.  Identification of 13,14-dihydro-15-oxo-prostaglandin F2 alpha in the circulation during infusions of bradykinin and prostaglandin E2 in man.

Authors:  S E Barrow; J Cockcroft; C T Dollery; N E Hickling; J M Ritter
Journal:  Br J Pharmacol       Date:  1987-05       Impact factor: 8.739

7.  Bradykinin-stimulated prostaglandin synthesis in conscious rabbits.

Authors:  J B Warren; J M Ritter; N E Hickling; S E Barrow
Journal:  Br J Pharmacol       Date:  1987-12       Impact factor: 8.739

8.  Acute effect of inhaled bradykinin on tracheobronchial clearance in normal humans.

Authors:  R Polosa; A Hasani; D Pavia; J E Agnew; C K Lai; S W Clarke; S T Holgate
Journal:  Thorax       Date:  1992-11       Impact factor: 9.139

9.  Comparative nasal effects of bradykinin, kallidin and [Des-Arg9]-bradykinin in atopic rhinitic and normal volunteers.

Authors:  K Rajakulasingam; R Polosa; S T Holgate; P H Howarth
Journal:  J Physiol       Date:  1991-06       Impact factor: 5.182

10.  Inhibition of bradykinin-induced vasodilation in human forearm vasculature by icatibant, a potent B2-receptor antagonist.

Authors:  J R Cockcroft; P J Chowienczyk; S E Brett; N Bender; J M Ritter
Journal:  Br J Clin Pharmacol       Date:  1994-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.